Harm reduction - The cannabis paradox

Harm Reduction Journal

Volumn 2, Issue , 2005, Pages

  Melamede, Robert J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 AMINOBUTYRIC ACID; ALCOHOL; BARBITURIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABIS; COCAINE; CP 55040; CYTOCHROME P450; CYTOCHROME P450 2A; DRONABINOL; ENDOCANNABINOID; FIBROBLAST GROWTH FACTOR RECEPTOR; HALOPERIDOL; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEVODOPA; LIPOPROTEIN LIPASE; MORPHINE; NEUROLEPTIC AGENT; NICOTINE; NICOTINIC RECEPTOR; OPIATE DERIVATIVE; RESERPINE; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR;

AUTOIMMUNE DISEASE; BEHAVIOR DISORDER; BRAIN DISEASE; CANCER THERAPY; CANNABIS ADDICTION; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DIGESTIVE SYSTEM; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SELF ADMINISTRATION; DYSKINESIA; DYSPHORIA; ENDOCRINE SYSTEM; EUPHORIA; EVIDENCE BASED MEDICINE; EVOLUTION; EXOCRINE GLAND; GENITAL SYSTEM; HALLUCINATION; HARM REDUCTION; HOMEOSTASIS; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNE SYSTEM; LUNG CANCER; MEDICAL LITERATURE; MENTAL STRESS; MORALITY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL SYSTEM; NERVOUS SYSTEM; NONHUMAN; PAIN; PARKINSON DISEASE; PEER REVIEW; REGULATORY MECHANISM; REVIEW; REWARD; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SMOKING; SOMNOLENCE; SURVIVAL; TH1 CELL;

EID: 27344450819     PISSN: 14777517     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-2-17     Document Type: Review

References (137)

1. Lindsay GB, Rainey J: Psychosocial and pharmacologic explanations of nicotine's "gateway drug" function. J Sch Health. 1997, 67:123-126.
2. Ginzler JA, Cochran BN, Domenech-Rodriguez M, Cauce AM, Whitbeck LB: Sequential progression of substance use among homeless youth: an empirical investigation of the gateway theory. Subst Use Misuse. 2003, 38:725-758.
3. Herstek J, Watson A, Kammer C: Pharmaceuticals issue brief: medical marijuana: year end report-2002. Issue Brief Health Policy Track Serv. 2002, 1-12.
4. Russo E, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, Kirlin KA: Chronic Cannabis Use in the Compassionate Investigational New Drug Program:An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis. Journal of Cannabis Therapeutics. 2002, 3-56.
5. Mechoulam R, Gaoni Y: The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett. 1967, 12:1109-1111.
6. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC: Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990, 87:1932-1936.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990, 346:561-564.
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992, 258:1946-1949.
9. Di M, Bisogno T, De Petrocellis L: Endocannabinoids: new targets for drug development. Curr Pharm Des. 2000, 6:1361-1380.
10. Cravatt BF, Lichtman AH: Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol. 2003, 7:469-475.
11. Baker D, Pryce G, Giovannoni G, Thompson AJ: The therapeutic potential of cannabis. Lancet Neurol. 2003, 2:291-298.
12. Cannabis-Based Medicines - GW Pharmaceuticals: High CBD, High THC, Medicinal Cannabis - GW Pharmaceuticals, THC:CBD. Drugs R D. 2003, 4:306-309.
13. Elphick MR, Satou Y, Satoh N: The invertebrate ancestry of endocannabinoid signalling: an orthologue of vertebrate cannabinoid receptors in the urochordate Ciona intestinalis. Gene. 2003, 302:95-101.
14. Elphick MR, Egertova M: The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci. 2001, 356:381-408.
15. Sepe N, De Petrocellis L, Montanaro F, Cimino G, Di Marzo V: Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. Biochim Biophys Acta. 1998, 1389:101-111.
16. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V: Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience. 1999, 92:377-387.
17. Guzman M, Sanchez C: Effects of cannabinoids on energy metabolism. Life Sci. 1999, 65:657-664.
18. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD: Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol. 2002, 133:124-131.
19. Ralevic V: Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. Eur J Pharmacol. 2003, 472:1-21.
20. Hiley CR, Ford WR: Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction? Br J Pharmacol. 2003, 138:1183-1184.
21. Brown TT, Dobs AS: Endocrine effects of marijuana. J Clin Pharmacol. 2002, 42:90S-96S.
22. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, Mascolo N, Di Marzo V, Capasso F: Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology. 2002, 123:227-234.
23. Dmitrieva N, Berkley KJ: Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci. 2002, 22:7147-7153.
24. Grotenhermen F, Muller-Vahl K: IACM 2nd Conference on Cannabinoids in Medicine. Expert Opin Pharmacother. 2003, 4:2367-2371.
25. Habayeb OM, Bell SC, Konje JC: Endogenous cannabinoids: metabolism and their role in reproduction. Life Sci. 2002, 70:1963-1977.
26. Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D: Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature. 2000, 408:96-101.
27. Rottanburg D, Robins AH, Ben-Arie O, Teggin A, Elk R: Cannabis-associated psychosis with hypomanic features. Lancet. 1982, 2:1364-1366.
28. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999, 19:2987-2995.
29. Lim G, Sung B, Ji RR, Mao J: Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain. 2003, 105:275-283.
30. Caberlotto L, Rimondini R, Hansson A, Eriksson S, Heilig M: Corticotropin-Releasing Hormone (CRH) mRNA Expression in Rat Central Amygdala in Cannabinoid Tolerance and Withdrawal: Evidence for an Allostatic Shift? Neuropsychopharmacology. 2003,
31. Croxford JL: Therapeutic potential of cannabinoids in CNS disease. CNS Drugs. 2003, 17:179-202.
32. Wilson RI, Nicoll RA: Endocannabinoid signaling in the brain. Science. 2002, 296:678-682.
33. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM: Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 2001, 57:2108-2111.
34. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernandez-Ruiz J: Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem. 2003, 84:1097-1109.
35. Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME: Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004, 5:33-39.
36. Milton NG: Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett. 2002, 332:127-130.
37. Guzman M, Sanchez C, Galve-Roperh I: Control of the cell survival/death decision by cannabinoids. J Mol Med. 2001, 78:613-625.
38. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D: Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 2003,
39. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ: The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003,
40. Iversen L: Cannabis and the brain. Brain. 2003, 126:1252-1270.
41. Ware MA, Gamsa A, Persson J, Fitzcharles MA: Cannabis for chronic pain: case series and implications for clinicians. Pain Res Manag. 2002, 7:95-99.
42. Wilson RI, Nicoll RA: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001, 410:588-592.
43. Nadler V, Mechoulam R, Sokolovsky M: The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett. 1993, 162:43-45.
44. Hampson AJ, Grimaldi M, Axelrod J, Wink D: Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998, 95:8268-8273.
45. Patel HC, Boutin H, Allan SM: Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci. 2003, 992:39-47.
46. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, Rothwell NJ: Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci. 2003, 23:6470-6474.
47. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995, 215:89-97.
48. Williams EJ, Walsh FS, Doherty P: The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol. 2003, 160:481-486.
49. Glass M: The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2001, 25:743-765.
50. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC: Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci. 2003, 30:201-205.
51. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000, 404:84-87.
52. Baker D, Pryce G: The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs. 2003, 12:561-567.
53. Klein TW, Newton CA, Nakachi N, Friedman H: Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol. 2000, 164:6461-6466.
54. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993, 365:61-65.
55. Munckhof WJ, Konstantinos A, Wamsley M, Mortlock M, Gilpin C: A cluster of tuberculosis associated with use of a marijuana water pipe. Int J Tuberc Lung Dis. 2003, 7:860-865.
56. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB: Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol. 1989, 23:73-81.
57. Fernandez JR, Allison DB: Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs. 2004, 5:430-435.
58. van Oosten BW, Killestein J, Mathus-Vliegen EM, Polman CH: Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Mult Scler. 2004, 10:330-331.
59. Berdyshev EV, Boichot E, Germain N, Allain N, Anger JP, Lagente V: Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol. 1997, 330:231-240.
60. Melamede RJ: Indications for Cannabinoids: Autoimmune Diseases. Cannabis and Cannabinoids, Pharmacology, Toxicology and Therapeutic Potential. 2000,
61. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agro A, Maccarrone M: Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci. 2002, 22:6900-6907.
62. Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D: The CB1 Cannabinoid Receptor Agonist, HU-210, Reduces Levodopa-Induced Rotations in 6-Hydroxydopamine-Lesioned Rats. Pharmacol Toxicol. 2003, 93:66-70.
63. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM: Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 2000, 14:1432-1438.
64. Mechoulam R, Hanu L: The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag. 2001, 6:67-73.
65. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001, 323:16-21.
66. Guzman M, Sanchez C, Galve-Roperh I: Cannabinoids and cell fate. Pharmacol Ther. 2002, 95:175-184.
67. Parolaro D, Massi P, Rubino T, Monti E: Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids. 2002, 66:319-332.
68. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M: Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002, 100:627-634.
69. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003, 111:43-50.
70. Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M: Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 1998, 436:6-10.
71. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V: Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 2000, 141:118-126.
72. Wilson RGJ, Tahir SK, Mechoulam R, Zimmerman S, Zimmerman AM: Cannabinoid enantiomer action on the cytoarchitecture. Cell Biol Int. 1996, 20:147-157.
73. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M: Inhibitory effects of cannabinoid CBI receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 2003, 17:1771-1773.
74. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V: Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003, 125:677-687.
75. Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004, 64:5617-5623.
76. Gardner B, Zhu LX, Sharma S, Tashkin DP, Dubinett SM: Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J. 2003,
77. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, Simone DA: A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain. 2003, 103:175-186.
78. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ: Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003, 102:211-216.
79. Berman J, Lee J, Cooper M, Cannon A, Sach J, McKerral S, Taggart M, Symonds C, Fishe K, Birch R: Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Anaesthesia. 2003, 58:938.
80. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JB: The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol. 2000, 129:227-230.
81. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997, 389:816-824.
82. Walker JM, Huang SM: Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids. 2002, 66:235-242.
83. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K: The neurobiology of cannabinoid analgesia. Life Sci. 1999, 65:665-673.
84. Rice AS, Farquhar-Smith WP, Nagy I: Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids. 2002, 66:243-256.
85. Wade DT, Robson P, House H, Makela P, Aram J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003, 17:21-29.
86. Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y, Yildiz O: Topical cannabinoid enhances topical morphine antinociception. Pain. 2003, 105:303-308.
87. Hall W, Degenhardt L: Medical marijuana initiatives: are they justified? How successful are they likely to be? CNS Drugs. 2003, 17:689-697.
88. Abrams DI: Medical marijuana: tribulations and trials. J Psychoactive Drugs. 1998, 30:163-169.
89. Grotenhermen F: Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003, 42:327-360.
90. Novotny M, Lee ML, Bartle KD: A possible chemical basis for the higher mutagenicity of marijuana smoke as compared to tobacco smoke. Experientia. 1976, 32:280-282.
91. Wu TC, Tashkin DP, Djahed B, Rose JE: Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med. 1988, 318:347-351.
92. Sidney S, Quesenberry CPJ, Friedman GD, Tekawa IS: Marijuana use and cancer incidence (California, United States). Cancer Causes Control. 1997, 8:722-728.
93. Minna JD: Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest. 2003, 111:31-33.
94. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP: Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001, 7:833-839.
95. Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva C, Fernandez-Acenero MJ, Aragones J, Huffman JW, Jorcano JL, Guzman M: Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 2003, 17:529-531.
96. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz SP: Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 1999, 8:1071-1078.
97. D G, J SL, S G: Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds. Journal of Cannabis Therapeutics. 4:7-27.
98. L G, R A, J W. Respiratory Harms of Smoked Cannabis. Adelaide Australia: Drug and Alcohol Services Council; 2000:
99. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L: Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986, 38:21-43.
100. Yamamoto I, Watanabe K, Narimatsu S, Yoshimura H: Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol. 1995, 27:741-746.
101. Bornheim LM, Everhart ET, Li J, Correia MA: Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol. 1994, 48:161-171.
102. Tretyakova N, Matter B, Jones R, Shallop A: Formation of benzo[a]pyrene diol epoxide-DNA adducts at specific guanines within K-ras and p53 gene sequences: stable isotope-labeling mass spectrometry approach. Biochemistry. 2002, 41:9535-9544.
103. Pellinen P, Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen O, Lang MA, Pasanen M: Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol. 1994, 270:35-43.
104. Deutsch DG, Tombler ER, March JE, Lo SH, Adesnik M: Potentiation of the inductive effect of phenobarbital on cytochrome P450 mRNAs by cannabidiol. Biochem Pharmacol. 1991, 42:2048-2053.
105. Cichewicz DL, McCarthy EA: Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 2003, 304:1010-1015.
106. Marchese G, Casti P, Ruiu S, Saba P, Sanna A, Casu G, Pani L: Haloperidol, but not clozapine, produces dramatic catalepsy in {Delta}9-THC-treated rats: possible clinical implications. Br J Pharmacol. 2003,
107. Khanna P, Gupta MB, Gupta GP, Sanwal GG, Ali B: Influence of chronic oral intake of cannabis extract on oxidative and hydrolytic metabolism of xenobiotics in rat. Biochem Pharmacol. 1991, 41:109-113.
108. Prigogine I. From Being to Becoming. San Fransisco: W.H. Freeman; 1980:
109. Park B, McPartland JM, Glass M: Cannabis, cannabinoids and reproduction. Prostaglandins Leukot Essent Fatty Acids. 2004, 70:189-197.
110. Lepore M, Vorel SR, Lowinson J, Gardner EL: Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci. 1995, 56:2073-2080.
111. Tanda G, Munzar P, Goldberg SR: Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci. 2000, 3:1073-1074.
112. Justinova Z, Tanda G, Redhi GH, Goldberg SR: Self-administration of Delta(9)-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 2003, 169:135-140.
113. Fattore L, Cossu G, Martellotta CM, Fratta W: Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl). 2001, 156:410-416.
114. Ameri A: The effects of cannabinoids on the brain. Prog Neurobiol. 1999, 58:315-348.
115. Gardner EL: Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids. 2002, 121:267-290.
116. Marinelli M, Piazza PV: Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci. 2002, 16:387-394.
117. Di S, Malcher-Lopes R, Halmos KC, Tasker JG: Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci. 2003, 23:4850-4857.
118. Whitlow CT, Freedland CS, Porrino LJ: Functional consequences of the repeated administration of Delta(9)-tetrahydrocannabinol in the rat. Drug Alcohol Depend. 2003, 71:169-177.
119. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B: The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002, 418:530-534.
120. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN: Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl). 2003, 168:164-169.
121. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999, 283:401-404.
122. Norwood CS, Cornish JL, Mallet PE, McGregor IS: Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol. 2003, 465:105-114.
123. Vigano D, Grazia Cascio M, Rubino T, Fezza F, Vaccani A, Di Marzo V, Parolaro D: Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology. 2003, 28:1160-1167.
124. Yamaguchi T, Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y, Watanabe S, Yamamoto T: Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res. 2001, 909:121-126.
125. Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W: CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behav Brain Res. 1999, 104:141-146.
126. Balerio GN, Aso E, Berrendero F, Murtra P, Maldonado R: Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci. 2004, 20:2737-2748.
127. Basavarajappa BS, Hungund BL: Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol Alcohol. 2004,
128. Le Foll B, Goldberg SR: Cannabinoid CB1 antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 2004,
129. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G: Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002, 325:1199.
130. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W: Cannabis use and mental health in young people: cohort study. BMJ. 2002, 325:1195-1198.
131. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P: Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci. 2002, 252:86-92.
132. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V: Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003, 2:5.
133. Torrey EF, Yolken RH: The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both? Brain Behav Immun. 2001, 15:401-410.
134. Jones-Brando L, Torrey EF, Yolken R: Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003, 62:237-244.
135. Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R: Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol. 2001, 419:207-214.
136. Mechoulam R, Spatz M, Shohami E: Endocannabinoids and neuroprotection. Sci STKE. 2002, 2002:RE5.
137. Krylatov AV, Uzhachenko RV, Maslov LN, Bernatskaya NA, Makriyannis A, Mechoulam R, Pertwee RG, Sal'nikova OM, Stefano JB, Lishmanov Y: Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bull Exp Biol Med. 2002, 133:122-124.